Financials and Corporate
Number of shares and voting rights of Innate Pharma as at March 19, 2015
Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) charter, Innate Pharma...
Annual results 2014: stronger cash position and expanded clinical portfolio
€50m capital increase in June subscribed by specialized investors Cash horizon to the end of 2017 Acquisition of IPH2201, anti-NKG2A antibody, and start of Phase II clinical development Expected in...
Number of shares and voting rights of Innate Pharma as at December 31, 2014
Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) charter, Innate Pharma...
Full-year report on Innate Pharma’s liquidity contract with Gilbert Dupont
Under the liquidity contract entrusted by Innate Pharma to Gilbert Dupont, the following assets appeared on the liquidity account as at December 31, 2014: - 33,310 shares of Innate Pharma, and - 233...
Innate Pharma announces its financial calendar for 2015 as well as its participation in upcoming investor conferences
Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, announces...
Financial information for the third quarter of 2014
Cash, cash equivalent and financial instruments amounting to 74.7 million euros Cash horizon to end of 2017 unchanged Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate...
First half of 2014: broadened clinical portfolio and strengthened cash position
Acquisition in February 2014 of IPH2201, anti-NKG2A antibody, a Phase II-ready first-in-class checkpoint inhibitor Successful €50m capital increase subscribed by specialized investors Cash and cash...
Innate Pharma appoints Pierre Dodion as Chief Medical Officer and member of the Executive committee
Marcel Rozencweig becomes President of Innate Pharma Inc., based in the US Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class...
Number of shares and voting rights of Innate Pharma as at June 30, 2014
Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) charter, Innate Pharma...